News


 

NJ TOP DOCS 2022, DR. BRIAN MEHLING AND DR. PAVEL YUFIT SPECIALIZE IN TRAUMA TREATMENT

NJ Top Docs has reviewed and approved board-certified orthopedic surgeons, Brian Mehling, MD and Pavel Yufit, MD of Mehling Orthopedics for 2022. Both are fellows of the American Academy of Orthopedic Surgeons and specialize in trauma treatment. They are also members of the Orthopaedic Trauma Association.

Their practice, Mehling Orthopedics is an orthopedic trauma practice dedicated to creating individualized treatment plans for traumatic injuries and disabilities.

Dr. Mehling started his path in medicine through undergraduate study at Harvard University, obtaining his Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State University.

Completing his degree of medicine at Wright State University School of Medicine, Dr. Mehling received post graduate education through residencies and fellowships at St. Joseph’s Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a Ph.D. in Chemistry (which he is currently completing at Seton Hall University).

Dr. Mehling operates practices in northern New Jersey and Long Island, New York where he is on staff at Good Samaritan Hospital, Hackensack University Medical Center, Hackensack University Medical Center at Pascack Valley, Hackensack Meridian Palisades Medical Center, Hudson Regional Hospital, St. Joseph’s Medical Center, and St. Joseph’s Wayne Medical Center.

Dr. Yufit is fluent in Russian as well as English. He is involved with orthopedic research and participates in hospital-based orthopedic trauma studies to create better-individualized care plans that improve patient outcomes during treatment.

Dr. Yufit’s medical education began at the New York University School of Medicine. He then went on to complete his orthopedic surgery residency at New York Medical College at St. Vincent’s Hospital in the Manhattan, Brooklyn, Queens boroughs of New York City. After finishing his residency, Dr. Yufit was accepted into a competitive orthopedic trauma fellowship program at the University of Louisville in Louisville, Kentucky.


WORLD-RENOWNED STEM CELL RESEARCHER, BRIAN MEHLING, MD, SET TO ATTEND THE ANNUAL WORLD ECONOMIC FORUM IN DAVOS

ZURICH, Switzerland – May 4, 2022 – Brian Mehling, MD, a world-renowned stem cell researcher, board-certified orthopedic trauma surgeon, board-certified in anti-aging medicine, and founder of Blue Horizon International (BHI), will be attending the Annual World Economic Forum (WEF) in Davos from May 22-26. This will be Dr. Mehling’s ninth year attending the global conference.

The 52nd Annual Meeting will convene on the theme “Working Together, Restoring Trust,” with the aim to address economic, environmental, political and social fault-lines exacerbated by the COVID-19 pandemic.

Dr. Mehling and his team will be available onsite to share insights on the current and upcoming breakthroughs within the stem cells arena, as pertinent to the technology revolution and the future of the world.

“Stem cell therapies are, without a doubt, the future of medicine. I believe they will become the preferred substitutes for many surgical, pharmacological, and rehabilitative medical services,” shared Dr. Brian Mehling, Founder of Blue Horizon International. “The importance of research and the key direction that it will take will truly shape the way patients with chronic conditions, disorders, and acute diseases are treated.”

WEF began as a forum to generate ideas and solutions to help shape the global, regional, and industry agendas. The event attracts top-level business leaders from all over the world. Attendees include C-suite executives from corporations, heads of state and government, leaders of international organizations, civil society and religious organizations, academia, the media, and the arts.

Onsite interviews with Dr. Mehling at WEF will be available upon request and handled on a first-come, first-serve basis. To learn more about WEF, please visit: http://www.weforum.org


BLUE HORIZON INTERNATIONAL AND MEHLING ORTHOPEDICS TO EXHIBIT AT AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS ANNUAL MEETING IN CHICAGO

Brian Mehling, M.D. and Pavel Yufit, M.D., orthopedic surgeons with practices in New York and New Jersey, are scheduled to attend the 2022 Annual Meeting of the American Academy of Orthopaedic Surgeons in Chicago, Illinois from March 22-26, 2022 at the McCormick Place Convention Center. The booth number is 1904.

This is the world’s largest meeting of orthopaedic surgeons, researchers, and allied health professionals. The meeting offers physicians the opportunity to exchange ideas with their colleagues and learn about cutting-edge technology in their field.

Dr. Mehling is also the chief medical officer at BHI Therapeutic Sciences, LLC, a company that offers a novel method of arthritis therapy using a patient’s own stromal vascular fraction (SVF) cells including mesenchymal stem cells and Wharton’s Jelly mesenchymal stem cells. 

BHI Therapeutic Sciences and Blue Horizon International (BHI) will exhibit at the conference to introduce data outcomes from its program located at Malacky Hospital in Slovakia. 

“Stem cell therapy is primarily intended for patients with a diagnosis of joint osteoarthritis, whether being a gonarthrosis or coxarthrosis of first and second degree. Malacky Hospital is the only medical institute performing treatment of hip and knee osteoarthrosis with stem cells using the technology of BHI,” said Dr. Mehling.

Doreen Santora, CEO of BHI and BHI Therapeutic Sciences, LLC, who will be also attending the AAOS meeting added, “Malacky Hospital is a private hospital located in the western part of Slovakia, just a short car ride from Vienna. It offers high-quality, comprehensive, and customized healthcare solutions to organizations and individuals and it is staffed with expertly-trained medical professionals and is one of the premiere hospitals in Central Europe.”

Mehling Orthopedics performs complex orthopedic fracture surgeries, including high velocity fractures, open fractures and complex pelvic ring injuries as well as general orthopedic and sports medicine surgeries.  Their team of experts delivers specialized care for orthopedic traumatic injuries. With all doctors certified by the American Board of Orthopedic Surgeons, they are committed to providing the finest medical care possible. For more information, please visit www.mehlingorthopedics.com.

BHI Therapeutic Sciences, LLC is currently offering cord blood, Wharton’s Jelly mesenchymal stem cells, bone marrow and adipose stem cell derived treatments at Malacky Hospital in Slovakia and in Jamaica. More information, please visit www.bhisciences.com.

The American Academy of Orthopaedic Surgeons (AAOS) provides education and practice management services for orthopaedic surgeons and allied health professionals. The Academy serves as an advocate for improved patient care and informs the public about the science of orthopaedics and it serves more than 39,000 members worldwide. For more information, please visit www.aaos.org.


BRIAN MEHLING, MD SLATED TO PARTICIPATE IN THE 19TH ANNUAL WORLD CONGRESS OF SOCIETY FOR BRAIN MAPPING AND THERAPEUTICS

Breaking Boundaries of Science, Technology, Medicine, Art, and Healthcare Policy meeting being held in LA March 10-13

Brian Mehling, MD, founder and chief medical officer of BHI Therapeutic Sciences, will virtually present on three topics at the 19th Annual World Congress of Society for Brain Mapping and Therapeutics. The meeting, entitled Breaking Boundaries of Science, Technology, Medicine, Art, and Healthcare Policy, will be held at the Los Angeles Convention Center, March 10-13.

Dr. Mehling will speak on the following: Safety study of Cultured Wharton’s Jelly Mesenchymal Stem Cells, Umbilical cord-derived stem cell therapy for multiple sclerosis treatment – a single subject case study, and Mesenchymal stem cell therapy for drowning induced hypoxic brain injury – A pediatric case report study of recovery.

Dr. Mehling is a board-certified American orthopedic trauma surgeon, researcher, and philanthropist. He is spearheading groundbreaking research in stem cell therapy focused on treatment and research using stem cells. He is also board-certified in anti-aging and regenerative medicine.

“We are focused on bringing advanced stem cell therapies within reach of a wider audience, “said Dr. Mehling. We envision a future in which stem cells are preferred over many surgical, pharmacological, and rehabilitative medical services,” he added. He and his colleagues are conducting clinical investigations to evaluate the safety and efficacy of adult stem cells in therapy of chronic inflammation, musculoskeletal conditions, stroke, spinal cord injury and other medical conditions.

This program is jointly Sponsored by Johns Hopkins University School of Medicine and Saint Louis University School of Medicine for Continuing Medical Education (CME) including 700+ presentations (live and virtual),13 keynotes, three panel discussions, and two bio-skills labs (Brain and Spine).

BHI Therapeutic Sciences (BHITS) is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells (those that are harvesting from an umbilical cord in the case of a C-Section, bringing no injury or risk to mother or baby).

Stem cells are a special kind of cell that can be used to regenerate the human body without drugs or surgery, treating the leading diseases and injuries shortening our life spans and causing millions of people to live in chronic pain.


BHI CEO PARTICIPATES IN PATIENT SAFETY WORKSHOP SPONSORED BY THE JOINT COMMISSION

Doreen Santora, RN, MHA, chief executive officer of Blue Horizon International (BHI) and its subsidiaries, including BHI Therapeutic Sciences, recently participated the Joint Commission International (JCI) program titled Managing Patient Safety Events: A Root Cause Analysis Workshop.

The two-day, live virtual workshop provided participants with the knowledge, skills, and strategies to establish a standardized approach to managing patient safety events, including sentinel events.

“BHI Therapeutic Sciences is committed to providing the highest quality and safest care,” said Brian Mehling, MD, founder and chief medical officer of BHI. “I applaud our leadership and our team for always seeking new information and education in order to provide better clinical outcomes and experiences for our patients,” he said.

Doreen Santora has more than 30 years of healthcare management experience. A registered nurse with a Master of Science degree in health administration, she serves as the Chief Executive Officer of Blue Horizon International (BHI) and all its subsidiaries. Most recently, Ms. Santora was recognized as a top nurse by the International Nurses Association and is featured in the publication Worldwide Leaders in Healthcare. She received this honor for her outstanding achievements, commitment to education, and demonstrated leadership in her field.

BHI specializes in bringing quality stem cell, regenerative, and related biologic technologies and therapies to emerging and established markets in a safe and ethical manner. She is responsible for the oversight of the day-to-day operations of BHI and places a strong emphasis on quality assurance and patient satisfaction.

Under her leadership, BHI has opened two successful stem cell therapy clinics in Jamaica and Slovakia. 

Ms. Santora focuses on providing outstanding medical care in a high quality, patient friendly environment. Prior to her position here, she served as senior vice president of operations at one of the busiest and most respected healthcare institutions in the United States, Hackensack University Medical Center. She was responsible for the growth and development of several nationally and internationally clinical programs that received numerous healthcare awards and distinctions.

The Joint Commission is the recognized global leader for healthcare accreditation. JCI is the author of rigorous international standards on quality and patient safety. These standards serve as the foundation of an evaluation process that helps healthcare organizations measure, assess, and continuously improve performance.


BRIAN MEHLING, MD PASSES ANTI-AGING AND REGENERATIVE MEDICINE BOARD CERTIFICATION

Brian Mehling, MD has successfully completed all components of the Board Certification in the field of Anti-Aging and Regenerative Medicine.

Dr. Mehling is the founder and chief medical officer of Mehling Orthopedics and BHI Therapeutic Sciences (BHITS). He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He spearheads groundbreaking research in stem cell therapy. Notably, BHITS is currently engaged in an FDA Investigational New Drug trial for stroke, using human umbilical cord blood (hUCB) stem cells. 

“Cellular medicine is in high demand and stem cells have the potential to treat a wide range of diseases. Stem cells are essentially “blank slate” cells that possess the remarkable potential to differentiate to any one of the billions of cells that form the diverse tissues of the human body. In addition, stem cells have the power to divide virtually without limits and convert or develop into specialized cells that can replace injured or damaged tissue.”

Completing his degree of medicine at Wright State University School of Medicine, Dr. Mehling received post graduate education through residencies and fellowships at St. Joseph’s Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a Ph.D. in Chemistry (which he is currently completing at Seton Hall University).

Founded in 1992 by Dr. Ronald Klatz and Dr. Robert Goldman, The American Academy of Anti-Aging Medicine (A4M) is rooted in a forward-focused mission to redefine modern medicine, The American Academy of Anti-Aging Medicine (A4M) is the established global leader for continuing medical education in longevity medicine, metabolic resilience, and whole-person care. 

 

Brian Mehling, M.D. and BHI Therapeutic Sciences Team Published in the Journal of Clinical Medicine Research

Osteoarthritis is the most common form of arthritis, affecting millions of people worldwide. It happens when the protective cartilage that cushions your bones wears down over time. Osteoarthritis most commonly affects hands, knees, hips, and spine. Researchers and clinicians from BHI Therapeutic Sciences, USA and Blue Horizon International, Slovakia recently concluded cell-based therapy shows promising results in the regeneration of injured cartilage and serves as an anti-inflammatory for the affected joint.

The paper, “A Retrospective Study of Stromal Vascular Fraction Cell Therapy for Osteoarthritis” was recently published in the Journal of Clinical Medicine Research.“Our study of 350 subjects with hip and knee osteoarthritis showed a significant improvement in pain levels and mobility at 3, 6, and 12 months compared to 7 days after autologous stromal vascular fraction (SVF) cell therapy,” said Brian Mehling, M.D., one of the authors of the study and the chief medical officer of BHI Therapeutic Sciences.

The study was approved by the Institutional Review Board of the Institute of Regenerative and Cellular Medicine (IRCM-2-17-137) and by the Ministry of Health of the Slovak Republic.
“The treatment demonstrated a strong safety profile with no severe adverse events or complications reported,” said Marina Manvelyan, Ph.D., clinical research scientist at BHI Therapeutic Sciences. “Interestingly, the results of the study show that SVF cell therapy was more effective in subjects with arthritis stage III compared to arthritis stages I, II, and IV,” she added.
The authors of the paper are Brian Mehling, Milan Hric, Adriana Salatkova, Robert Vetrak, Doreen Santora, Miriama Ovariova, Renata Mihalyova, and Marina Manvelyan. BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells.

The Journal of Clinical Medicine is an international, open access, and peer-reviewed journal that concentrates on general medical research and clinical practice. The journal aims to publish scientifically written, evidence-based articles from all disciplines of medical sciences and clinical practice, and nursing, preventive medicine, epidemiology, healthcare research, etc. All articles are rigorously peer-reviewed. The journal is indexed in PubMed and PubMed Central (PMC, US National Library of Medicine National Institutes of Health).

 

NJ Top Docs 2020, Dr. Brian Mehling and Dr. Pavel Yufit

Specialize in Trauma Treatment 

NJ Top Docs has reviewed and approved board-certified orthopedic surgeons, Brian Mehling, MD and Pavel Yufit, MD of Mehling Orthopedics for 2020. Both are fellows of the American Academy of Orthopedic Surgeons and specialize in trauma treatment. They are also members of the Orthopaedic Trauma Association.

Their practice, Mehling Orthopedics is an orthopedic trauma practice dedicated to creating individualized treatment plans for traumatic injuries and disabilities.

Dr. Mehling started his path in medicine through undergraduate study at Harvard University, obtaining his Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State University.

Completing his degree of medicine at Wright State University School of Medicine, Dr. Mehling received post graduate education through residencies and fellowships at St. Joseph’s Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a Ph.D. in Chemistry (which he is currently completing at Seton Hall University).

Dr. Mehling operates practices in northern New Jersey and Long Island, New York where he is on staff at Good Samaritan Hospital, Hackensack University Medical Center, Hackensack University Medical Center at Pascack Valley, Hackensack Meridian Palisades Medical Center, Hudson Regional Hospital, St. Joseph’s Medical Center, and St. Joseph’s Wayne Medical Center.

Dr. Yufit is fluent in Russian as well as English. He is involved with orthopedic research and participates in hospital-based orthopedic trauma studies to create better-individualized care plans that improve patient outcomes during treatment.

Dr. Yufit’s medical education began at the New York University School of Medicine. He then went on to complete his orthopedic surgery residency at New York Medical College at St. Vincent’s Hospital in the Manhattan, Brooklyn, Queens boroughs of New York City. After finishing his residency, Dr. Yufit was accepted into a competitive orthopedic trauma fellowship program at the University of Louisville in Louisville, Kentucky.

 

PAVEL YUFIT, MD RECEIVES NATIONAL CERTIFICATION AS DIPLOMATE IN ORTHOPEDIC SURGERY 

Pavel Yufit, MD, a board-certified orthopedic trauma surgeon and a partner at Mehling Orthopedics, was recently recertified by the National Board of Physicians and Surgeons as a diplomate in orthopaedic surgery.

Dr. Yufit was fellowship trained in trauma under David Seligson, M.D. in the prestigious University of Louisville Orthopaedic Trauma Fellowship program.

Prior to his fellowship, Dr. Yufit competed his residency in orthopedic surgery at New York Medical College/St. Vincent’s Hospital, Manhattan/Brooklyn/Queens region. He received his medical degree from New York University School of Medicine and earned his Bachelor of Arts degree summa cum laude in biochemistry and molecular biology from Boston University.

Dr. Yufit is also an Assistant Professor in the Department of Orthopedic Surgery at the Hackensack Meridian School of Medicine at Seton Hall University.
Involved in orthopedic research, Dr. Yufit participates in hospital-based orthopedic trauma studies in order to create care plans that will help improve outcomes.
He is also a fellow of the American Academy of Orthopedic Surgeons and a member of the Orthopaedic Trauma Association.

Dr. Yufit was named a 2018, 2019, and 2020 NJ Top Doc.

He has privileges at Hackensack University Medical Center, Hackensack, NJ; Hackensack Meridian Health at Pascack Valley, Westwood, NJ; Hackensack Meridian Health at Mountainside, Montclair, NJ; Hudson Regional Hospital, Secaucus, NJ; Hackensack Meridian Health Palisades Medical Center, North Bergen, NJ; Mount Sinai St. Luke’s Roosevelt Hospital Center, NYC; and Good Samaritan Hospital, West Islip, NY.

Dr. Yufit is fluent in English and Russian.

NJ Top Doc, Dr. Pavel Yufit Specializes in Trauma Treatment 

NJ Top Docs has reviewed and approved board-certified orthopedic surgeon, Pavel Yufit, MD of Mehling Orthopedics for 2020. Dr. Yufit is a fellow of the American Academy of Orthopedic Surgeons and specializes in trauma treatment. He is also a member of the Orthopaedic Trauma Association.

His practice, Mehling Orthopedics is an orthopedic trauma practice dedicated to creating individualized treatment plans for traumatic injuries and disabilities.

Dr. Yufit is fluent in Russian as well as English. He is involved with orthopedic research and participates in hospital-based orthopedic trauma studies to create better-individualized care plans that improve patient outcomes during treatment.

Dr. Yufit’s medical education began at the New York University School of Medicine. He then went on to complete his orthopedic surgery residency at New York Medical College at St. Vincent’s Hospital in the Manhattan, Brooklyn, Queens boroughs of New York City. After finishing his residency, Dr. Yufit was accepted into a competitive orthopedic trauma fellowship program at the University of Louisville in Louisville, Kentucky.

Pavel Yufit, MD Receives Faculty Appointment at Hackensack Meridian School of Medicine

Pavel Yufit, MD, a board-certified orthopedic trauma surgeon and a partner at Mehling Orthopedics, was recently appointed to the Hackensack Meridian School of Medicine at Seton Hall University. Dr. Yufit is an Assistant Professor in the Department of Orthopedic Surgery. Dr. Yufit was fellowship trained in trauma under David Seligson, M.D. in the prestigious University of Louisville Orthopaedic Trauma Fellowship program. Prior to his fellowship, Dr. Yufit completed his residency in orthopedic surgery at New York Medical College/St. Vincent’s Hospital, Manhattan/Brooklyn/Queens region. He received his medical degree from New York University School of Medicine and earned his Bachelor of Arts degree summa cum laude in biochemistry and molecular biology from Boston University. Involved in orthopedic research, Dr. Yufit participates in hospital-based orthopedic trauma studies in order to create care plans that will help improve outcomes.


He is a fellow of the American Academy of Orthopedic Surgeons, a member of the Orthopaedic Trauma Association, and a diplomate of the National Board of Physicians and Surgeons in orthopaedic surgery. Dr. Yufit was recently named a 2018, 2019, and 2020 NJ Top Doc. Dr. Yufit has privileges at Hackensack University Medical Center, Hackensack, NJ; Hackensack Meridian Health at Pascack Valley, Westwood, NJ; Hackensack Meridian Health at Mountainside, Montclair, NJ; Hudson Regional Hospital, Secaucus, NJ; Hackensack Meridian Health Palisades Medical Center, North Bergen, NJ; Mount Sinai St. Luke’s Roosevelt Hospital Center, NYC; and Good Samaritan Hospital, West Islip, NY. Dr. Yufit is fluent in English and Russian.

 

BHI THERAPEUTIC SCIENCES SCIENTIFIC ADVSIORY BOARD CHAIRMAN RECEIVES APPROVAL TO USE STEM CELL PRODUCT IN CLINICAL TRIALS 

A Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) product, developed by Wuhan Hamilton Biotechnology Co., Ltd., recently passed inspection by the China National Institute for Food and Drug Control. As a result, the UC-MSCs are a qualified product for application in clinical trials.

Dongecheng Wu, MD, Ph.D., manager and chief scientist of Wuhan Hamilton Biotechnology Co., Ltd. and his team will begin a study entitled “Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis.” Dr. Wu is also the chairman of the Scientific Advisory Board of BHI Therapeutic Sciences.

“Stem cells have been shown to migrate to sites of injury and inflammation where they are believed to support the survival of damaged cell and inhibit the immune responses,” said Dr. Wu. “Stem cell application in clinical trials shows promising results in therapy of neurological, musculoskeletal, cardiovascular and metabolic diseases,” he added.

The study will be conducted at Union Hospital, Tongji Medical College Huazhing University of Science and Technology. This study is the first clinical research project registered in Hubei Province with the China Medical Biotechnology Association.

Brian Mehling, MD, founder and chief medical officer of the BHI Therapeutic Sciences and long-time scientific partner with Dr. Wu, said “Stem cell research is the most exciting option in the field of regenerative medicine being tested for efficacy in treating a variety of health issues where the body’s own response to traditional treatment isn’t sufficient to restore health and optimum function.”

“Together with Dr. Wu, we are focused on bringing advanced stem cell therapies within reach of a wider audience, “said Dr. Mehling. We envision a future in which stem cells are preferred over many surgical, pharmacological, and rehabilitative medical services,” he added.

Dr. Mehling is a practicing American orthopedic trauma surgeon, researcher, and member of the prestigious International Society for Stem Cell Research. He is spearheading groundbreaking research in stem cell therapy focused on treatment and research using stem cells.

Dr. Wu is a Professor at Wuhan University School of Basic Medical Science and a Chu Tian Scholar.

BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells.   Its stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Results show its cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions. Multiple studies of umbilical cord blood derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results. The Food and Drug Administration (FDA) has given BHITS approval to proceed with an Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. For more information, please visit www.bhisciences.com

 

BRIAN MEHLING, MD RECEIVES 2020 BEST OF WEST ISLIP AWARD

Brian Mehling, MD, an orthopedic trauma surgeon, has been selected for the 2020 Best of West Islip Award in the Physicians & Surgeons category by the West Islip Award Program.

Each year, the West Islip Award Program identifies companies and individuals that have achieved exceptional marketing success in their local community and business category. They enhance the positive image of small business through service to their customers and the community. As a result, the recipients help make the West Islip area a great place to live, work, and play.

Dr. Mehling is the founder and chief medical officer of Mehling Orthopedics and BHI Therapeutic Sciences (BHITS). He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He is also spearheading groundbreaking research in stem cell therapy. Notably, BHITS is currently engaged in an FDA Investigational New Drug trial for stroke, using human umbilical cord blood (hUCB) stem cells.

Various sources of information were gathered and analyzed to choose the winners in each category. The 2020 West Islip Award Program focuses on quality, not quantity. Winners are determined based on the information gathered both internally by the West Islip Award Program and data provided by third parties.

Dr. Mehling started his path in medicine through undergraduate study at Harvard University, obtaining his Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State University.

“While I appreciate being recognized with this award, it is more of an honor to know that we are providing the highest quality care to our patients” said Dr. Mehling.


Completing his degree of medicine at Wright State University School of Medicine, Dr. Mehling received post graduate education through residencies and fellowships at St. Joseph’s Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a Ph.D. in Chemistry (which he is currently completing at Seton Hall University). Dr. Mehling is also a member of the prestigious International Society for Stem Cell Research (ISSCR).

Mehling Orthopedics is an orthopedic trauma practice dedicated to creating individualized treatment plans for traumatic injuries and disabilities. With convenient locations in Hackensack, New Jersey, and West Islip, New York, Mehling Orthopedics provides specialized care for orthopedic trauma and sports-related injuries.

The experienced board-certified orthopedic surgeons at Mehling Orthopedics understand that patients need individualized treatment and follow-up care from only the finest medical professionals available. That’s why the team has hired fellowship-trained experts with experience in the latest advances in biomedical processes, autologous stem cell treatments, arthroscopic, and minimally invasive techniques. The team’s physician assistants are specialized in orthopedic trauma and sports medicine.

At Mehling Orthopedics, patient satisfaction is a top priority. With highly-skilled, compassionate physicians, state-of-the-art medical equipment, and the most advanced orthopedic treatment options available, the team makes each one of their patients feel like a member of the family.

In addition to the practice, the Mehling Orthopedics team holds surgical privileges at Hackensack Meridian Health, Hackensack Meridian Health Palisades Medical Center, Hackensack University Medical Center, Hackensack University Medical Center at Pascack Valley, Hudson Regional Hospital, St. Joseph’s Regional Medical Center, and Mount Sinai St. Luke’s and Mount Sinai West.

Brian Mehling, MD, and Pavel Yufit, MD, are also board-certified by the American Board of Orthopedic Surgeons and members of the American Association of Orthopedic Surgeons. To learn more about the services available at Mehling Orthopedics, visit www.mehlingorthopedics.com

About West Islip Award Program

The West Islip Award Program is an annual awards program honoring the achievements and accomplishments of local businesses throughout the West Islip area. Recognition is given to those companies that have shown the ability to use their best practices and implemented programs to generate competitive advantages and long-term value.

The West Islip Award Program was established to recognize the best of local businesses in our community. Our organization works exclusively with local business owners, trade groups, professional associations and other business advertising and marketing groups. Our mission is to recognize the small business community's contributions to the U.S. economy.

 

 

BRIAN MEHLING, MD AND BHI THERAPEUTIC SCIENCES
TO PRESENT RESEARCH AT AAOS ANNUAL MEETING

Orthopedic surgeon Brian Mehling, MD and his research team at BHI Therapeutic Sciences will exhibit at the American Academy of Orthopedic Surgeons 2020 Annual Meeting, March 24 – 28, at the Orange County Convention Center in Orlando, Florida.

The team will present the results of their study entitled “Adipose Tissue-Derived Stromal Vascular Fraction Cells Application in Subjects with Osteoarthritis and Rheumatoid Arthritis: Retrospective Chart Review Study.” Their results will be presented at booth #1004 located in the West Concourse of the convention center.

“Musculoskeletal disorders are one of the most common reasons that patients seek medical care. The most common musculoskeletal problems are osteoarthritis and rheumatoid arthritis, said Dr. Mehling. “Adipose tissue-derived Stromal Vascular Fraction (SVF) cell therapy is a promising therapeutic option for rheumatoid arthritis and osteoarthritis,” he added.

Dr. Mehling and his team conducted the current retrospective chart review study to analyze the therapeutic efficacy of SVF cells administration in 350 subjects with rheumatoid arthritis and osteoarthritis. In the period from 2015 to 2018, 350 subjects received an intra- articular injection of autologous SVF cells at the Malacky Hospital (Bratislava, Slovakia). The hospital is fully licensed by the Ministry of Health of the Slovak Republic to offer cord blood, bone marrow and adipose stem cell derived treatments at Malacky Hospital in Bratislava, Slovakia. The study was approved by the Ministry of Health of the Slovak Republic and by the Institutional Review Board of the Institute of Regenerative and Cellular Medicine (IRCM-2017- 137).

“Charts were reviewed, and information from subjects’ pain and mobility assessment scales, conducted seven days, three, six and 12 months after therapy, was collected in the data collection forms,” said Marina Manvelyan, Ph.D., clinical research scientist, BHI Therapeutic Sciences.   

Assessment of pain and mobility was conducted seven days, three, six and 12 months after SVF cell therapy. Significant decrease in subjects’ pain levels and improvement in mobility were observed three, six and 12 months compared to seven days after therapy. The therapy demonstrated a strong safety profile with no severe adverse events or complications reported.

Dr. Mehling is a practicing American orthopedic trauma surgeon and researcher. He is spearheading groundbreaking research in stem cell therapy. Notably, BHITS is currently engaged in an FDA Investigational New Drug trial for stroke, using human umbilical cord blood (hUCB) stem cells.


Dr. Mehling started his path in medicine through undergraduate study at Harvard University, obtaining his Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State University.


Completing his degree of medicine at Wright State University School of Medicine, Dr. Mehling received post graduate education through residencies and fellowships at St. Joseph’s Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a Ph.D. in Chemistry (which he is currently completing at Seton Hall University).


Dr. Mehling operates practices in northern New Jersey and Long Island, New York where he is on staff at Good Samaritan Hospital, Hackensack University Medical Center, Hackensack University Medical Center at Pascack Valley, Hackensack Meridian Palisades Medical Center, Hudson Regional Hospital, St. Joseph’s Medical Center, and St. Joseph’s Wayne Medical Center.

Founded in 1933, the Academy is the preeminent provider of musculoskeletal education to orthopaedic surgeons and others in the world. Its continuing medical education activities include a world-renowned Annual Meeting, multiple CME courses held around the country and at the Orthopaedic Learning Center, and various medical and scientific publications and electronic media materials.

 

 

BRIAN MEHLING, MD AND MARINA MANVELYAN, PH.D RECEIVE MEMBERSHIP

TO THE PRESTIGIOUSINTERNATIONAL SOCIETY FOR STEM CELL RESEARCH

Hackensack, NJ – BHI Therapeutic Sciences is pleased to announce that Brian Mehling, MD, Chief Medical Officer and Marina Manvelyan, Ph.D., Clinical Research Scientist have been accepted as members of the prestigious International Society for Stem Cell Research (ISSCR).

Members of the ISSCR have been sharing global stem cell science for more than 15 years. With roughly 4,000 members from more than 60 countries, the ISSCR is the pre-eminent global, cross-disciplinary, science-based organization dedicated to stem cell research and its translation to the clinic. The organization promotes global collaboration among the world’s most talented and committed stem cell scientists and physicians, and plays a catalyzing role in the development of effective new treatments.

According to George Q. Daley, MD, Ph.D., dean, Harvard Medical School and professor, Boston Children’s Hospital & Dana Farber Cancer Institute, “Core strengths of the ICCSR include its scientific integrity and excellence, and its outstanding membership comprised of research leaders worldwide.”

Dr. Mehling is the founder and chief medical officer of BHI Therapeutic Sciences.  He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He is spearheading groundbreaking research in stem cell therapy focused on treatment and research using stem cells.

“We are focused on bringing advanced stem cell therapies within reach of a wider audience, “said Dr. Mehling. We envision a future in which stem cells are preferred over many surgical, pharmacological, and rehabilitative medical services,” he added.


Dr. Mehling and his colleagues are conducting clinical investigations to evaluate the safety and efficacy of adult stem cells in therapy of chronic inflammation, musculoskeletal conditions, stroke, spinal cord injury and other medical conditions.

Dr. Manvelyan has 15 years of experience in biomedical research and is the author of more than 40 research papers.

She started her research career as a research scientist at Yerevan State University (Armenia) and University Hospital of Jena, Institute of Human Genetic (Germany).

As a Clinical Research Scientist at BHI Therapeutic Sciences, she is conducting scientific research and clinical investigations of adult stem cell therapy for various medical conditions.

The ISSCR promotes the highest scientific and ethical standards and is dedicated to integrity in the rigor and quality of the research community’s scientific work.

BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells.   Its stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Results show its cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions. Multiple studies of umbilical cord blood derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results. The Food and Drug Administration (FDA) has given BHITS approval to proceed with an Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. For more information, please visit www.bhisciences.com

 

 

BRIAN MEHLING, MD TO PRESENT SPINAL CORD STEM CELL RESEARCH AT ANNUAL MEETING OF THE SOCIETY FOR BRAIN MAPPING AND THERAPEUTICS

Brian Mehling, MD has been invited to present his research at the 17th Annual World Congress of the Society for Brain Mapping and Therapeutics being held at the JW Marriott, in Los Angeles, California from Friday March 20 - Sunday, March 22.

The conference will bring together physicians, scientists, policy makers, funding agencies and industry to further the advances and applications in brain and spinal cord mapping and image guide therapies (operative and non-operative).

Dr. Mehling is the founder and chief medical officer of BHI Therapeutic Sciences. He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He is spearheading groundbreaking research in stem cell therapy focused on treatment and research using stem cells.

His presentation is entitled Umbilical Cord Blood Stem Cell Therapy for Spinal Cord Injury and the objective of this retrospective cohort study was to analyze the muscle, nerve, urinary, and gastrointestinal function in subjects with spinal cord injury, treated with either human umbilical cord blood-derived mononuclear cells or conventional therapy. "Allogeneic umbilical cord blood mononuclear cell therapy in 30 subjects with spinal cord injury showed significant improvement in pain and temperature sensation, lower limb muscle strength, bladder function, and gastrointestinal function compared to a conventional therapy group," Dr. Mehling said.

"We are focused on bringing advanced stem cell therapies within reach of a wider audience," said Dr. Mehling. We envision a future in which stem cells are preferred over many surgical, pharmacological, and rehabilitative medical services," he added.

Dr. Mehling and his colleagues are conducting clinical investigations to evaluate the safety and efficacy of adult stem cells in therapy of chronic inflammation, musculoskeletal conditions, stroke, spinal cord injury and other medical conditions.

BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells. Its stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Results show its cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions. Multiple studies of umbilical cord blood derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results. The Food and Drug Administration (FDA) has given BHITS approval to proceed with an Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. For more information, please visit www.bhisciences.com.

The Society for Brain Mapping and Therapeutics (SBMT) is a non-profit society organized for the purpose of encouraging basic and clinical scientists who are interested in areas of Brain Mapping, engineering, stem cell, nanotechnology, imaging and medical device to improve the diagnosis, treatment and rehabilitation of patients afflicted with neurological disorders.

This society promotes the public welfare and improves patient care through the translation of new technologies/therapies into lifesaving diagnostic and therapeutic procedures. The society is committed to excellence in education, and scientific discovery. The society achieves its mission through multi-disciplinary collaborations with government agencies, patient advocacy groups, educational institutes and industry as well as philanthropic organization.

Our Locations

Choose your preferred location